Who’s Driving the Value-Based Kidney Care Train—And Where's It Headed?
Tim Fitzpatrick
Founder and writer building a platform for ideas, innovations, and investments to transform kidney health for 1 billion people
In some ways the kidney care industry feels like a train picking up speed—hurtling forward with new policies, earnings reports, and market shifts. But the tracks ahead are unclear, and it’s not obvious who’s driving these days. Where are we even headed? Are we making progress toward better outcomes, or are we just looping around the same track? From the outside, the train is accelerating toward the horizon and into uncharted territory. From the inside, the landscape looks the same as it has for a long time. Fortunately, we've been doing our best to make sense of it all and have some big updates to share, including a long-awaited VBC database and deeper analyses to help you stay ahead in 2025.
Keep exploring, and thank you all for being here.
Value-Based Kidney Care Directory: Now Live
We know kidney care has long been a proving ground for value-based care, but how is it going? Who’s actually leading the way? Our new Value-Based Kidney Care Directory is the most comprehensive resource available, mapping out key players, strategic partnerships, and innovative care models driving the transformation of kidney care. Whether you’re a provider looking for potential partners and collaborators, an investor assessing the market landscape, or a policymaker seeking insights to better serve your constituents, this directory provides a one-stop view of who’s shaping the future. It highlights the most significant organizations engaged in kidney care payment reform and innovation, offering a clear snapshot of the industry's evolving framework. Bookmark this resource to stay informed as the space continues to develop— we'll be updating it regularly.
KCC in Numbers: Breaking Down the Data
We've written a bit about the Kidney Care Choices (KCC) model lately, and will have even more to say once the PY23 results become available. But how do kidney care entities (KCEs) stack up so far? What’s happening in terms of CKD and ESRD spend and outcomes, and where are we seeing real movement? Our latest analysis takes a data-driven approach to unpacking the current state of KCEs, examining financial performance, patient outcomes, and key operational and quality trends. The report dives deep into growth and performance patterns by affiliated dialysis or care coordination organization, an increasingly competitive landscape with a broad range of outcomes. Whether you're tracking expansion strategies, monitoring reimbursement shifts, or evaluating the impact of new regulations, this summary article aims to provide the essential numbers to watch ahead of the upcoming PY23 results release.
Signals Recap: What You Might Have Missed
Every other Sunday, we break down the biggest kidney care news, industry moves, and emerging trends in one place. If you missed last week’s recap, we covered Humana’s latest earnings and its expanded in-home kidney care program with Monogram, the FDA’s approval of the first xenotransplant trials, and the fourth-ever pig kidney transplant performed in a human. We also highlighted new research linking 1,000 genes to kidney disease, a Congressional investigation into global kidney trade disparities, and MediBeacon’s FDA approval for its GFR monitoring device. Beyond policy and research, the recap featured discussions on Trump 2.0’s potential health policies, Epic’s partnership with Donate Life America, and Travere’s planned FDA submission for FSGS treatment.
These biweekly insights help make sense of the rapid changes happening across the kidney landscape—don’t miss out on the next issue coming next Sunday.
What’s Next?
The next few weeks will bring major developments in kidney care, from fresh earnings reports and payer strategies to new policy movements and leadership changes in Washington. We’re keeping a close eye on:
How to support Signals
###
Decades of clinical operations experience | Contract and Project Manager with global experience | Proven Success at delivering projects on time | Champion for Customer Satisfaction and DE&I | Educator
5 天前Tim Fitzpatrick a recent JAMA article confirms what many of us have been warning about: VBC is failing patients while lining the pockets of corporate middlemen. Companies like Evergreen Nephrology, Satellite Healthcare / WellBound, Monogram Health, Panoramic Health, and Strive Health claim to be “patient-centered,” but in reality, they’re just insurer-driven entities pushing cost-cutting policies that harm care quality. VBC was supposed to improve outcomes by rewarding better care, but in practice, it prioritizes financial incentives over actual patient well-being. For dialysis and CKD patients, this is disastrous. These companies don’t focus on transplant access or early intervention—they keep patients locked into long-term dialysis because that’s where the money is. VBC doesn’t lower costs or improve care—it just shifts profits to administrative middlemen. Physicians are forced to operate within rigid, cost-driven structures, limiting patient options and treatment access. The winners? Insurers and corporate healthcare giants.https://www.dhirubhai.net/posts/parkejeff_vbc-jama-dialysis-activity-7300002990764027904-kp2G?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAR-rnIBeXFOWDuBn7eV7oi3NRvJE_m5F3g
State Grassroots Coordinator-Arizona Coordinating Body at Association of Diabetes Care & Education Specialists
6 天前Love this
Interventional Nephrologist | Medical Consultant & Advisor
6 天前Outstanding update Tim Fitzpatrick It seems the overwhelming players as far as number of KCEs has been InterWell and Davita, I presume that has to do with the prior relationships that both Fresenius and Davita had made. However, as far as patients served Somatus, Strive and HealthMap are right up there with them. What do you think has lead to success of some of these VBC players over others? Is is amount of capital raised? The strategic investors that came along for the ride? A lot these people in these C-suites are Davita alums.
Founder and writer building a platform for ideas, innovations, and investments to transform kidney health for 1 billion people
1 周Now Live: The VB Kidney Care Directory: Companies, Funding, Growth, Outcomes, Performance, Key Metrics: ?? https://trfitzpatrick.com/p/table-value-based-kidney-care-part